2nd Mar 2005 08:19
LiDCO Group Plc02 March 2005 For immediate release 2 March 2005 LiDCO GROUP PLC CHANGE OF PR COMPANY LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, ispleased to announce the appointment of Buchanan Communications as its financialPR company. Buchanan is a financial communications agency with a market leading position inthe healthcare and medtech arena. For more information please contact: LiDCO Group Plc 020 7749 1500 Terry O'Brien, CEO ([email protected]) Theresa Wallis, Chairman ([email protected]) Buchanan Communications Tim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Durlacher Ltd Grant Harrison (Head of Corporate Broking) 020 7459 3600 Notes for Editors: LiDCO is a leading supplier of minimally invasive, computer-based hemodynamicmonitoring equipment and disposables used primarily for the management ofcritical care and cardiovascular risk hospital patients. The Company's current products are: • the LiDCOplus and PulseCO monitors, computer-based platforms for displaying a range of real-time continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume following calibration with: • the LiDCO disposable for accurately determining cardiac output in a minimally-invasive manner Application of the LiDCO technology to reduce complications and costs ofsurgery: Post surgical 'Goal Directed Optimisation' is an application of the LiDCOplusmonitor. The 'Goal' is to target a higher than normal delivery of the oxygencarried by the blood's red cells to the body tissues. Achievement of this 'Goal'has been shown to reduce the complications associated with surgery. To achieve 'Goal Directed Optimisation' the LiDCOplus monitor measures the absolute and beatto beat changing levels of oxygen delivery through use of an arterial linealready inserted in a small vessel at the wrist of most major surgery patients.The monitor user interface has been specifically designed to help the clinicianor nurse to rapidly and appropriately administer intra venous fluids and drugsthat increase oxygen delivery to levels that ensure the repayment of any oxygendeficit incurred during major surgery. The advantages of using the LiDCOplustechnology are that the oxygen delivery targets can be both set and achievedminimally invasively using existing staff without the use of more invasivecatheters that have additional risks to the patient and costs to the hospital. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
LID.L